Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 4, 2008, Pages 855-863

  Kendall, Anne ^a   Anderson, Helen ^b,c   Dunbier, Anita K ^b,c   Mackay, Alan ^c   Dexter, Tim ^c   Urruticoechea, Ander ^d   Harper Wynne, Catherine ^e   Dowsett, Mitch ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^e MAIDSTONE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; LETROZOLE;

ARTICLE; BREAST; BREAST BIOPSY; CONTROLLED STUDY; DNA MICROARRAY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PRIORITY JOURNAL; RNA EXTRACTION;

AROMATASE INHIBITORS; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; MIDDLE AGED; NITRILES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTMENOPAUSE; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 42149132680     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2718     Document Type: Article

References (36)

1. Thürlimann B, Keshaviah A, Coates A S, et al.; for the Breast International Group (BIG) 1-98 Collaborative Group. A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer. N Engl J Med 2005;353:2747-57.
2. ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
3. Coombes RC, Kilburn LS, Snowdon CF, et al.; on behalf of the Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-70.
4. Goss PE, Ingle JN, Martino S, et al. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-71.
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
6. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
7. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42.
8. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
9. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57.
10. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
11. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
12. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614-21.
13. MacKay A, Urruticoechea A, Dixon JM, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9:R37.
14. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
15. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
16. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
17. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
18. Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogenous cDNA. Proc Natl Acad Sci U S A 1990;87:1663-7.
19. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
20. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
21. Segal E, Friedman N, Koller D, Regev A. A module map showing conditional activity of expression modules in cancer. Nat Genet 2004;36:1090-8.
22. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
23. Miller WR, Larionov A, Renshaw L, et al. Aromatase inhibitors - gene discovery. J Steroid Biochem Mol Biol 2007;106:130-42.
24. Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003;39:462-8.
25. Shekhar MPV, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res 2001;61:1320-6.
26. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000;60:2562-6.
27. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144:4562-74.
28. Cicatiello L, Scafoglio C, Altucci L, et al. A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol 2004;32:719-75.
29. Wilson CL, Sims AH, Howell A, Miller CJ, Clarke RB. Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. Endocr Relat Cancer 2006;13:617-28.
30. Innes HE, Liu D, Barraclough R, et al. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br J Cancer 2006;94:1057-65.
31. Lacroix M, Leclercq G. About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer. Mol Cell Endocrinol 2004;219:1-7.
32. Ellis MJ, Coop A, Singh B, et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63:6523-31.
33. Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92.
34. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J Pathol 1999;188:237-44.
35. Anderson E, Clarke RB, Howell A. Estrogen responsiveness and control of normal human breast proliferation. J Mammary Gland Biol Neoplasia 1998;3:23-35.
36. Anderson E, Clarke RB. Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 2004;9:3-13.